Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oxo Chemie GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Required:
Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count \<= 200 cells/mm3.
Allowed:
PCP prophylaxis with aerosolized pentamidine in patients with CD4 count \> 200 cells/mm3, only at the discretion of the treating physician.
Patients must have:
HIV positivity.
Absolute CD4 count of 150 - 500 cells/mm3.
At least 6 months of prior zidovudine therapy.
No active opportunistic infection requiring ongoing therapy.
Life expectancy of at least 6 months.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Neoplasm other than basal cell carcinoma of the skin.
Clinically significant cardiac disease.
Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing.
Unwilling to comply with protocol requirements.
Patients with the following prior conditions are excluded:
History of myocardial infarction or arrhythmias.
Prior Medication:
Excluded within 2 weeks prior to study entry:
Antiretroviral agent or interferon.
Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic agents, or other drugs that can cause neutropenia or significant nephrotoxicity.
Rifampin or rifampin derivatives.
Systemic anti-infectives.
Required:
At least 6 months of prior zidovudine. Active drug or alcohol abuse.
